Premium
Fibrin glue system for brachytherapy of glioblastoma with RE‐88 and RE‐186 labeled microspheres
Author(s) -
Häfeli U. O.,
Pauer G. J.
Publication year - 2001
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.25804401236
Subject(s) - fibrin glue , microsphere , brachytherapy , glioblastoma , glue , fibrin , nuclear medicine , dosimetry , chemistry , in vivo , brain tissue , radiation therapy , biomedical engineering , medicine , surgery , materials science , cancer research , biology , microbiology and biotechnology , chemical engineering , engineering , immunology , composite material
Brain tumors such as glioblastoma recur in their original location in almost 50% of the cases. To prevent this we developed a radiopharmaceutical system that can be applied as a gel immediately after resection of a brain tumor to deliver local booster doses. The gel, which strongly adheres to tissue in the treatment area, consists of fibrin glue containing the β‐emitters Re‐188 and Re‐186 in microsphere‐bound form. Its radioisotope‐dependent maximum treatment range in tissue is 11 and 6 mm, respectively. The dosimetry of this fibrin glue system was determined using gafchromic film measurements. No toxic effects were seen in vivo, but histological examination showed dose‐dependent radiation effects. The effectiveness of Re‐188/Re‐186‐containing fibrin glue was demonstrated in a rodent glioblastoma model. All control animals died within 17 ± 3 days, whereas 60% of the treated animals survived 36 days, the final length of the experiment.